Literature DB >> 19454072

Essential tremor.

Joaquim Jos Ferreira1, Cristina Sampaio.   

Abstract

INTRODUCTION: Essential tremor is one of the most common movement disorders throughout the world, with prevalence in the general population of 0.4-3.9%. Although most people with essential tremor are only mildly affected, those who seek medical care are disabled to some extent, and most are socially handicapped by the tremor. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of drug treatments in people with essential tremor of the hand? We searched: Medline, Embase, The Cochrane Library and other important databases up to December 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 41 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding mirtazepine to other antitremor drugs; benzodiazepines; beta-blockers other than propranolol; botulinum A toxin-haemagglutinin complex; calcium channel blockers; carbonic anhydrase inhibitors; clonidine; flunarizine; gabapentin; isoniazid; Phenobarbital; primidone; propranolol; and topiramate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19454072      PMCID: PMC2943813     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  46 in total

1.  Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study.

Authors:  Rajesh Pahwa; Kelly E Lyons
Journal:  Mov Disord       Date:  2003-05       Impact factor: 10.338

2.  Topiramate in essential tremor: a double-blind, placebo-controlled trial.

Authors:  W G Ondo; J Jankovic; G S Connor; R Pahwa; R Elble; M A Stacy; W C Koller; L Schwarzman; S-C Wu; J F Hulihan
Journal:  Neurology       Date:  2006-01-25       Impact factor: 9.910

3.  A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.

Authors:  M F Brin; K E Lyons; J Doucette; C H Adler; J N Caviness; C L Comella; R M Dubinsky; J H Friedman; B V Manyam; J Y Matsumoto; S L Pullman; A H Rajput; K D Sethi; C Tanner; W C Koller
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

4.  Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial.

Authors:  W Ondo; C Hunter; K D Vuong; K Schwartz; J Jankovic
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

5.  New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide.

Authors:  D I Gunal; N Afşar; N Bekiroglu; S Aktan
Journal:  Neurol Sci       Date:  2000-10       Impact factor: 3.307

6.  A double-blind placebo-controlled trial of topiramate treatment for essential tremor.

Authors:  Gregory S Connor
Journal:  Neurology       Date:  2002-07-09       Impact factor: 9.910

7.  Primidone in essential tremor of the hands and head: a double blind controlled clinical study.

Authors:  L J Findley; L Cleeves; S Calzetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-09       Impact factor: 10.154

8.  A double-blind trial of clonazepam in benign essential tremor.

Authors:  C Thompson; A Lang; J D Parkes; C D Marsden
Journal:  Clin Neuropharmacol       Date:  1984       Impact factor: 1.592

9.  Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial.

Authors:  A Baruzzi; G Procaccianti; P Martinelli; R Riva; F Denoth; N Montanaro; E Lugaresi
Journal:  Neurology       Date:  1983-03       Impact factor: 9.910

10.  Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol.

Authors:  P N Leigh; D Jefferson; A Twomey; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-08       Impact factor: 10.154

View more
  1 in total

Review 1.  The treatment of tremor.

Authors:  Susanne A Schneider; Günther Deuschl
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.